Skip to content
IACH News
Prof. Mohamad Mohty – New treatments for refractrory acute GVHD
Dr. Eolia Brissot – Approval of maribvir for post-transplant cytomegalovirus infection
Prof. Sebastian Giebel – CAR T cells for adult ALL
Prof. Farhad Ravandi – MRD in AML
Prof. Iskra Pusic – Recent updated in Acute GVHD
Prof. Arnon Kater -State of the art therapy in CLL
Annalisa Ruggeri – Haplo versus matched unrelated transplant at the era of post-cyclophosphamide
Christopher Hourigan – How to distinguish to Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis?
Robert Zeiser – REACH3 trial results
Alex Lazaryan – Belumosudil’s FDA approval for cGVHD
Monzr Al Malki – The role of post cyclophosphamide, for GVHD prophylaxis, in the mismatched unrelated setting
Naveen Pemmaraju – Novel Therapeutic Approaches in BPDCN
Jurgen Kuball – Gammadelta T cells
Anna Sureda – Therapy of lymphomas, what’s new at EHA 2021
Nitin Jain – Therapy of CLL, what’s new at EHA 2021
Gram Jackson – Recently released paper on Improving prognostic assignment in older adults with MM
Mehdi Hamadani – Recently released ZUMA-7 trial results
Saad Usmani – Take-home messages, from ASCO, and EHA 2021
Luciano J. Costa – The role of auto in myeloma based on the ASCO 21 data
Jesus G. Berdeja – Results of the CARTITUDE-1 study
Arnon Nagler – Allo-transplant for AML: what’s new at EHA 2021
Mohamad Mohty – Advances in Multiple Myeloma as reported at EHA 2021
Ruben Mesa – Therapy of MPNs: what’s new at EHA 2021?
Dr. Jordan Gauthier – Results from Phase 3 TRANSFORM Trial
Dr. Jim Omel – The patient / cancer research advocate viewpoint from ASCO 2021
Prof. Mohamad Mohty – Multiple myeloma take home messages from ASCO 2021
Page load link